Trade IGM Biosciences, Inc. - IGMS CFD

Add to favourite

6.73

6.14%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.06

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

IGM Biosciences Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	7.17
Open*	7.13
1-Year Change*	-36.68%
Day's Range*	6.73 - 7.13
52 wk Range	3.81-26.08
Average Volume (10 days)	397.61K
Average Volume (3 months)	7.11M
Market Cap	604.96M
P/E Ratio	-100.00K
Shares Outstanding	65.79M
Revenue	1.85M
EPS	-4.99
Dividend (Yield %)	N/A
Beta	0.22
Next Earnings Date	Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 22, 2024	6.73	-0.45	-6.27%	7.18	7.18	6.65
Apr 19, 2024	7.17	-0.04	-0.55%	7.21	7.37	7.01
Apr 18, 2024	7.37	-0.61	-7.64%	7.98	8.05	7.07
Apr 17, 2024	8.07	-0.91	-10.13%	8.98	9.31	8.02
Apr 16, 2024	9.18	0.01	0.11%	9.17	9.43	8.90
Apr 15, 2024	9.37	0.50	5.64%	8.87	9.72	8.87
Apr 12, 2024	9.16	0.90	10.90%	8.26	9.23	8.22
Apr 11, 2024	8.34	0.18	2.21%	8.16	8.34	7.92
Apr 10, 2024	8.14	-0.34	-4.01%	8.48	8.51	7.90
Apr 9, 2024	8.72	0.10	1.16%	8.62	9.01	8.59
Apr 8, 2024	8.74	0.00	0.00%	8.74	9.09	8.56
Apr 5, 2024	8.74	0.06	0.69%	8.68	9.04	8.53
Apr 4, 2024	8.86	-0.12	-1.34%	8.98	9.44	8.82
Apr 3, 2024	9.01	0.03	0.33%	8.98	9.19	8.57
Apr 2, 2024	9.12	-0.11	-1.19%	9.23	9.32	8.80
Apr 1, 2024	9.43	-1.19	-11.21%	10.62	10.62	9.29
Mar 28, 2024	9.57	0.45	4.93%	9.12	9.67	9.12
Mar 27, 2024	9.25	0.57	6.57%	8.68	9.38	8.52
Mar 26, 2024	8.64	-0.09	-1.03%	8.73	8.76	8.14
Mar 25, 2024	8.67	-1.32	-13.21%	9.99	10.49	8.54

IGM Biosciences, Inc. Events

Time (UTC)	Country	Event
Friday, May 10, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 IGM Biosciences Inc Earnings Release Q1 2024 IGM Biosciences Inc Earnings Release Forecast - Previous -
Friday, June 21, 2024
Time (UTC) 15:00	Country US	Event IGM Biosciences Inc Annual Shareholders Meeting IGM Biosciences Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 IGM Biosciences Inc Earnings Release Q2 2024 IGM Biosciences Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	1.069	0	0	0	0
Total Operating Expense	229.025	165.323	83.28	44.498	22.791
Selling/General/Admin. Expenses, Total	49.736	38.297	18.25	9.241	3.829
Research & Development	179.289	127.026	65.03	35.257	18.962
Operating Income	-227.956	-165.323	-83.28	-44.498	-22.791
Other, Net	-0.181	0.159	1.925	1.365	0.08
Net Income Before Taxes	-221.102	-165.164	-81.355	-43.133	-22.711
Net Income After Taxes	-221.102	-165.164	-81.355	-43.133	-22.711
Net Income Before Extra. Items	-221.102	-165.164	-81.355	-43.133	-22.711
Net Income	-221.102	-165.164	-81.355	-43.133	-22.711
Income Available to Common Excl. Extra. Items	-221.102	-165.164	-81.355	-43.133	-22.711
Income Available to Common Incl. Extra. Items	-221.102	-165.164	-81.355	-43.133	-22.711
Diluted Net Income	-221.102	-165.164	-81.355	-43.133	-22.711
Diluted Weighted Average Shares	41.5439	33.4798	30.7483	30.4851	28.892
Diluted EPS Excluding Extraordinary Items	-5.32212	-4.93325	-2.64584	-1.41489	-0.78607
Dividends per Share - Common Stock Primary Issue					0
Diluted Normalized EPS	-5.32212	-4.93325	-2.64584	-1.41489	-0.78607
Revenue	1.069
Interest Income (Expense), Net Non-Operating	7.035

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0.448	0.522	0.372	0.331	0.366
Total Operating Expense	68.656	63.896	56.636	60.843	59.59
Selling/General/Admin. Expenses, Total	12.983	13.002	11.619	12.664	12.372
Research & Development	55.673	50.894	45.017	48.179	47.218
Operating Income	-68.208	-63.374	-56.264	-60.512	-59.224
Other, Net	0	-0.02	-0.058	0	0.629
Net Income Before Taxes	-64.314	-59.222	-52.576	-58.037	-58.595
Net Income After Taxes	-64.423	-59.309	-52.576	-58.037	-58.595
Net Income Before Extra. Items	-64.423	-59.309	-52.576	-58.037	-58.595
Net Income	-64.423	-59.309	-52.576	-58.037	-58.595
Income Available to Common Excl. Extra. Items	-64.423	-59.309	-52.576	-58.037	-58.595
Income Available to Common Incl. Extra. Items	-64.423	-59.309	-52.576	-58.037	-58.595
Diluted Net Income	-64.423	-59.309	-52.576	-58.037	-58.595
Diluted Weighted Average Shares	45.1229	44.5932	44.2711	44.0346	43.9191
Diluted EPS Excluding Extraordinary Items	-1.42772	-1.33	-1.18759	-1.31798	-1.33416
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-1.42772	-1.33	-1.18759	-1.31798	-1.33416
Revenue	0.448	0.522	0.372	0.331	0.366
Interest Income (Expense), Net Non-Operating	3.894	4.172	3.746	2.475

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	438.421	240.747	373.272	231.1	2.407
Cash and Short Term Investments	427.162	229.542	366.269	224.634	1.887
Cash & Equivalents	121.231	133.334	241.08	35.891	1.887
Total Receivables, Net				0.035	0.035
Prepaid Expenses	10.57	10.504	7.003	6.431	0.485
Total Assets	513.499	298.127	408.632	261.35	3.979
Property/Plant/Equipment, Total - Net	73.075	56.344	34.812	18.019	1.472
Property/Plant/Equipment, Total - Gross	85.4	62.897	37.101	19.283	2.139
Accumulated Depreciation, Total	-12.325	-6.553	-2.289	-1.264	-0.667
Other Long Term Assets, Total	2.003	1.036	0.548	0.258	0.1
Total Current Liabilities	44.685	27.78	17.24	8.875	8.89
Accounts Payable	2.512	5.584	7.924	3.087	0.164
Accrued Expenses	39.437	22.196	9.316	5.788	3.582
Notes Payable/Short Term Debt	0	0	0	0	5.027
Other Current Liabilities, Total	2.736			0	0.117
Total Liabilities	226.236	53.219	26.817	21.119	8.89
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	181.551	25.439	9.577	12.244	0
Total Equity	287.263	244.908	381.815	240.231	-4.911
Preferred Stock - Non Redeemable, Net					60.917
Common Stock	0.431	0.325	0.319	0.304	0.004
Additional Paid-In Capital	862.359	598.373	570.03	347.089	0.751
Retained Earnings (Accumulated Deficit)	-574.826	-353.724	-188.56	-107.205	-64.072
Other Equity, Total				0.043	-2.511
Total Liabilities & Shareholders’ Equity	513.499	298.127	408.632	261.35	3.979
Total Common Shares Outstanding	43.0823	32.498	31.9741	36.6957	28.892
Short Term Investments	305.931	96.208	125.189	188.743
Long Term Investments				11.973
Unrealized Gain (Loss)	-0.701	-0.066	0.026
Other Current Assets, Total	0.689	0.701

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	398.395	401.76	384.756	438.421	479.966
Cash and Short Term Investments	386.991	386.869	373.396	427.162	469.139
Cash & Equivalents	174.794	150.702	140.164	121.231	177.414
Short Term Investments	212.197	236.167	233.232	305.931	291.725
Prepaid Expenses	10.787	14.249	10.702	10.57	10.134
Total Assets	474.35	480.658	462.742	513.499	540.936
Property/Plant/Equipment, Total - Net	73.972	76.779	75.829	73.075	58.847
Property/Plant/Equipment, Total - Gross
Accumulated Depreciation, Total
Other Long Term Assets, Total	1.983	2.119	2.157	2.003	2.123
Total Current Liabilities	42.965	44.299	43.632	44.685	44.484
Accounts Payable	3.913	4.936	3.972	2.512	2.731
Accrued Expenses	34.139	34.618	36.063	39.437	36.996
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	220.488	222.051	223.312	226.236	212.761
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	177.523	177.752	179.68	181.551	168.277
Total Equity	253.862	258.607	239.43	287.263	328.175
Preferred Stock - Non Redeemable, Net		0	0		0
Common Stock	0.584	0.528	0.432	0.431	0.428
Additional Paid-In Capital	1014.1	957.089	873.48	862.359	850.772
Retained Earnings (Accumulated Deficit)	-760.547	-698.558	-634.135	-574.826	-522.25
Unrealized Gain (Loss)	-0.277	-0.452	-0.347	-0.701	-0.775
Total Liabilities & Shareholders’ Equity	474.35	480.658	462.742	513.499	540.936
Total Common Shares Outstanding	58.3852	52.7394	43.188	43.0823	42.8024
Long Term Investments
Other Current Assets, Total	0.617	0.642	0.658	0.689	0.693
Other Current Liabilities, Total	4.913	4.745	3.597	2.736	4.757

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-221.102	-165.164	-81.355	-43.133	-22.711
Cash From Operating Activities	-5.853	-124.982	-67.881	-45.116	-20.044
Cash From Operating Activities	6.075	4.484	1.025	0.597	0.278
Non-Cash Items	54.004	29.251	10.404	2.444	0.21
Changes in Working Capital	155.17	6.447	2.045	-5.024	2.179
Cash From Investing Activities	-225.644	15.461	58.289	-203.238	-0.788
Capital Expenditures	-10.206	-13.244	-17.502	-2.337	-0.788
Cash From Financing Activities	219.382	2.476	214.781	282.258	22.337
Financing Cash Flow Items	0.895	-0.65	-1.048	-2.094	0
Issuance (Retirement) of Stock, Net	218.487	3.126	215.829	269.352	17.337
Issuance (Retirement) of Debt, Net				15	5
Net Change in Cash	-12.115	-107.045	205.189	33.904	1.505
Cash Taxes Paid				0.297	0.035
Cash Interest Paid				0
Other Investing Cash Flow Items, Total	-215.438	28.705	75.791	-200.901

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-59.309	-221.102	-168.526	-110.489	-51.894
Cash From Operating Activities	-50.997	-5.853	32.005	72.418	-38.869
Cash From Operating Activities	1.664	6.075	4.177	2.668	1.224
Non-Cash Items	11.588	54.004	39.511	26.72	12.665
Changes in Working Capital	-4.94	155.17	156.843	153.519	-0.864
Cash From Investing Activities	69.824	-225.644	-206.833	-203.085	-19.123
Capital Expenditures	-3.937	-10.206	-7.511	-4.8	-2.977
Other Investing Cash Flow Items, Total	73.761	-215.438	-199.322	-198.285	-16.146
Cash From Financing Activities	0.075	219.382	218.9	218.603	0.072
Financing Cash Flow Items	0	0.895	0.477	0.477	-0.068
Issuance (Retirement) of Stock, Net	0.075	218.487	218.423	218.126	0.14
Net Change in Cash	18.902	-12.115	44.072	87.936	-57.92

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

IGM Biosciences, Inc. Company profile

About IGM Biosciences Inc

IGM Biosciences, Inc. is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of multiple diseases. It has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Financial summary

BRIEF: For the nine months ended 30 September 2021, IGM Biosciences Inc revenues was not reported. Net loss increased from $56.7M to $114.5M. Higher net loss reflects Research and development - Bala increase of 89% to $80.3M (expense), General and administrative - Balanc increase of 67% to $17.1M (expense), Stock-based Compensation in SGA increase from $2.9M to $9.7M (expense).

Industry:

Bio Therapeutic Drugs

325 E Middlefield Rd
MOUNTAIN VIEW
CALIFORNIA 94043-4003
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024